Electronic Health Records as a GPS for Healthcare
As patients are bombarded with more choice and information than ever, the burdened health system seems to lack the appropriate support to manage increasing demands for personalized and convenient care.
Today’s infographic comes to us from Publicis Health, and it demonstrates how electronic health records are an important piece in the puzzle to improve experiences for patients and providers alike.
At a Crossroads
As it stands, the current healthcare industry faces several challenges. Patients today have more complex needs and wants, while physicians are struggling to keep up.
- 25% of Americans have multiple chronic conditions.
- 63% of patients forget to adhere to medications.
- 40% of doctors feel that their work pace is chaotic.
- 60% of doctors feel that visits are too short to treat patients effectively.
Adding to these challenges, the healthcare industry is grappling with significant amounts of technological change, while also trying to keep costs in check. Between 2015 and 2017, hospitals lost $6.8 billion in operating income – that’s an average decline of nearly 40% in just two years.
A New Direction for Patient Care
Enter electronic health records (EHRs) – platforms used to conveniently store a patient’s health information and offer all sorts of services, from scheduling appointments and consultations to identifying patients at risk and guiding care decisions.
An improvement on physical paper charts, EHRs allow a patient’s medical history to be shared securely and instantly across different settings.
First conceived in 2009 under the Obama administration’s Health Information Technology for Economic and Clinical Health (HITECH) act, EHRs have rapidly evolved as they’ve been implemented in the industry, with 87% office-based doctors nationwide relying on the system.
Today, EHRs are a massive industry: the global market was worth $23.6 billion in 2016, and it’s expected to reach close to $33.3 billion by 2023. It’s clear their real capabilities are still just at the tip of the iceberg.
As technology progresses to incorporate artificial intelligence and big data into healthcare, the point of care for patients will likely extend beyond the four walls of a doctor’s office and out into the world. In other words, EHR systems act like a GPS, helping doctors and care teams navigate patient care more efficiently. This improves patient-doctor interactions, resulting in better outcomes.
Of course, there are always challenges to overcome. Here are a few key considerations for EHRs:
|What’s the Problem?||The Solve||Benefits|
|Apps aren’t for all ages||Conversational AI platforms||- All age groups are familiar with chat platforms
- Streamline user interactions
- Increases engagement
|Expensive professional health system resources||AI-powered virtual assistance||- Concierge services for patients
- Access accurate patient information
- Increases engagement and adherence
|Generic, one-way content||Personalized content||- Educational and relevant content, based on individual needs|
|Missed appointments or medication||Reminder services||- Supports optimal care
- Improves adherence
|Accessibility issues||Telemedicine or transportation services||- Enables patients with transportation challenges to receive the care they need|
Thinking Beyond EHR Systems
Capturing real world data and patient-reported outcomes will be important for wider applications, towards:
- A deeper understanding of patient journeys
- Informing clinical trial design and execution
- Better characterizing patient demographics
- Evaluating treatment options for sub-populations
In the future, healthcare and pharma companies could potentially use EHRs as one part of an entire suite of solutions to improve their workflow – and extend the point of care everywhere.
This is part six of a seven part series. Stay tuned for the final piece by subscribing to Visual Capitalist for free, as we wrap up the major transformative forces shaping the future of healthcare.
Visualizing Over A Century of Global Fertility
Global fertility has almost halved in the past century. Which countries are most resilient, and which have experienced the most dramatic changes over time?
Visualizing Over A Century of World Fertility
In just 50 years, world fertility rates have been cut in half.
This sea change can be attributed to multiple factors, ranging from medical advances to greater gender equity. But generally speaking, as more women gain an education and enter the workforce, they’re delaying motherhood and often having fewer children in the process.
Today’s interactive data visualization was put together by Bo McCready, the Director of Analytics at KIPP Texas. Using numbers from Our World in Data, it depicts the changes in the world’s fertility rate—the average number of children per woman—spanning from the beginning of the 20th century to present day.
A Demographic Decline
The global fertility rate fell from 5.25 children per woman in 1900, to 2.44 children per woman in 2018. The steepest drop in this shift happened in a single decade, from 1970 to 1980.
In the interactive graphic, you’ll see graphs for 200 different countries and political entities showing their total fertility rate (FTR) over time. Here’s a quick summary of the countries with the highest and lowest FTRs, as of 2017:
|Top 10 Countries||Fertility rate||Bottom 10 Countries||Fertility Rate|
|🇳🇪 Niger||7.13||🇹🇼 Taiwan||1.22|
|🇸🇴 Somalia||6.08||🇲🇩 Moldova||1.23|
|🇨🇩 Democratic Republic of Congo||5.92||🇵🇹 Portugal||1.24|
|🇲🇱 Mali||5.88||🇸🇬 Singapore||1.26|
|🇹🇩 Chad||5.75||🇵🇱 Poland||1.29|
|🇦🇴 Angola||5.55||🇬🇷 Greece||1.3|
|🇧🇮 Burundi||5.53||🇰🇷 South Korea||1.33|
|🇺🇬 Uganda||5.41||🇭🇰 Hong Kong||1.34|
|🇳🇬 Nigeria||5.39||🇨🇾 Cyprus||1.34|
|🇬🇲 Gambia||5.29||🇲🇴 Macao||1.36|
At a glance, the countries with the highest fertility are all located in Africa, while several Asian countries end up in the lowest fertility list.
The notable decade of decline in average global fertility can be partially traced back to the actions of the demographic giants China and India. In the 1970s, China’s controversial “one child only” policy and India’s state-led sterilization campaigns caused sharp declines in births for both countries. Though they hold over a quarter of the world’s population today, the effects of these government decisions are still being felt.
Population Plateau, or Cliff?
The overall decline in fertility rates isn’t expected to end anytime soon, and it’s even expected to fall past 2.1 children per woman, which is known as the “replacement rate”. Any fertility below this rate signals fewer new babies than parents, leading to an eventual population decline.
Experts predict that world fertility will further drop from 2.5 to 1.9 children per woman by 2100. This means that global population growth will slow down or possibly even go negative.
Africa will continue to be the only region with significant growth—consistent with the generous fertility rates of Nigeria, the DRC, and Angola. In fact, the continent is expected to house 13 of the world’s largest megacities, as its population expands from 1.3 billion to 4.3 billion by 2100.
The Big Pharma Takeover of Medical Cannabis
The Big Pharma industry is entering the cannabis space, by swapping patients for patents. But what are the impacts of such a takeover?
The Big Pharma Takeover of Medical Cannabis
As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.
Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.
Who are “Big Pharma”?
The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.
So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.
Could Cannabis be Sold Over the Counter?
The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.
Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:
- Multiple sclerosis
- Cancer side effects
As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.
As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.
Big Pharma’s Foray into Cannabis
Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.
Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.
|Company Rank||🇨🇦 Canadian Patents||Company Rank||🇺🇸 U.S. Patents|
|1. Novartis||21||1. Abbvie||59|
|2. Pfizer||14||2. Sanofie||39|
|3. GW Pharmaceuticals||13||3. Merck||35|
|4. Ericsson||13||4. Bristol-Myers Squibb||34|
|5. Merck||11||5. GW Pharmaceuticals||28|
|6. Solvay Pharmaceuticals||7||6. Pfizer||25|
|7. Kao Corporation||7||7. Hebrew University of Jerusalem||19|
|8. Ogeda SA||7||8. Roche||17|
|9. Sanofi||6||9. University of Connecticut||16|
|10. University of Connecticut||6||10. U.S. Health and Human Services||13|
It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.
Data is the Missing Link
While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.
Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.
Markets7 months ago
The Jeff Bezos Empire in One Giant Chart
Maps9 months ago
Mercator Misconceptions: Clever Map Shows the True Size of Countries
Advertising6 months ago
Meet Generation Z: The Newest Member to the Workforce
Misc9 months ago
24 Cognitive Biases That Are Warping Your Perception of Reality
Advertising5 months ago
How the Tech Giants Make Their Billions
Technology8 months ago
The 20 Internet Giants That Rule the Web
Chart of the Week7 months ago
Chart: The World’s Largest 10 Economies in 2030
Environment6 months ago
The World’s 25 Largest Lakes, Side by Side